SARS-CoV-2 vaccine candidates in rapid development

References

• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33. doi:10.1056/NEJMoa2001017. PubMed PMID: 31978945; PubMed Central PMCID: PMCPMC7092803.
   PubMed Web of Science ®Google Scholar
• Wevers BA, van der Hoek L Recently discovered human coronaviruses. Clin Lab Med. 2009 Dec;29(4):715–24. PubMed PMID: 19892230; PubMed Central PMCID: PMCPMC7131583. doi:10.1016/j.cll.2009.07.007.
   PubMed Web of Science ®Google Scholar
• Weston S, Frieman MB. COVID-19: knowns, unknowns, and questions. mSphere. 2020 Mar 18;5(2). doi:10.1128/mSphere.00203-20. PubMed PMID: 32188753; PubMed Central PMCID: PMCPMC7082143.
   PubMed Web of Science ®Google Scholar
• Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol 2020;11:298. PubMed PMID: 32265848; PubMed Central PMCID: PMCPMC7105881. doi:10.3389/fmicb.2020.00298.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270–73. doi:10.1038/s41586-020-2012-7. PubMed PMID: 32015507; PubMed Central PMCID: PMCPMC7095418.
   PubMed Web of Science ®Google Scholar
• Zhang YZ, Holmes EC. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell. 2020 Mar 26. doi:10.1016/j.cell.2020.03.035. PubMed PMID: 32220310.
   Web of Science ®Google Scholar
• Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009 Mar;7(3):226–36. PubMed PMID: 19198616; PubMed Central PMCID: PMCPMC2750777. doi:10.1038/nrmicro2090.
   PubMed Web of Science ®Google Scholar
• WHO Coronavirus Disease (COVID-19) dashboard 2020 World Health Organization; [ updated 2020 May 14]. [accessed 2020 Jul 15]. https://covid19.who.int/.
   Google Scholar
• Wu Y, Ho W, Huang Y, Jin D-Y, Li S, Liu S-L, Liu X, Qiu J, Sang Y, Wang Q, et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet. 2020;395(10228):949–50. doi:10.1016/s0140-6736(20)30557-2.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Current Bio 2020 Apr 6;30(7):1346–1351.e2. doi:10.1016/j.cub.2020.03.022. PubMed PMID: 32197085; PubMed Central PMCID: PMCPMC7156161. eng.
   PubMed Web of Science ®Google Scholar
• Tu C, Crameri G, Kong X, Chen J, Sun Y, Yu M, Xiang H, Xia X, Liu S, Ren T, et al. Antibodies to SARS coronavirus in civets. Emerg Infect Dis. 2004 Dec;10(12):2244–48. doi:10.3201/eid1012.040520. PubMed PMID: 15663874; PubMed Central PMCID: PMCPMC3323399. eng.
   PubMed Web of Science ®Google Scholar
• Ji JS. Origins of MERS-CoV, and lessons for 2019-nCoV. Lancet Planet Health. 2020;4(3):e93. doi:10.1016/s2542-5196(20)30032-2.
   PubMedGoogle Scholar
• Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou -J-J, Li N, Guo Y, Li X, Shen X, et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature. 2020 May 7;583:286–89. doi:10.1038/s41586-020-2313-x. PubMed PMID: 32380510.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Cui H, Gao Z, Liu M, Lu S, Mkandawire W, Narykov O, Sun M, Korkin D. Structural genomics of SARS-CoV-2 indicates evolutionary conserved functional regions of viral proteins. Viruses 2020 Mar 25;12(4):360. doi:10.3390/v12040360. PubMed PMID: 32218151.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang P, Wang G, Cheng W, Chen J, Zhang X. Recent advances of therapeutic targets and potential drugs of COVID-19. Die Pharmazie. 2020 May 1;75(5):160–62. doi:10.1691/ph.2020.0431. PubMed PMID: 32393419; eng.
   Web of Science ®Google Scholar
• Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 2020 Feb 25;12(3):254. doi:10.3390/v12030254. PubMed PMID: 32106567.
   PubMed Web of Science ®Google Scholar
• Li K, Wohlford-Lenane CL, Channappanavar R, Park J-E, Earnest JT, Bair TB, Bates AM, Brogden KA, Flaherty HA, Gallagher T, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):E3119–e3128. doi:10.1073/pnas.1619109114. PubMed PMID: 28348219; PubMed Central PMCID: PMCPMC5393213. eng.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620. doi:10.1038/s41467-020-15562-9. PubMed PMID: 32221306; PubMed Central PMCID: PMCPMC7100515.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020 Apr 16;181(2):281–292 e6. doi:10.1016/j.cell.2020.02.058. PubMed PMID: 32155444; PubMed Central PMCID: PMCPMC7102599.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020 Mar 13;367(6483):1260–63. doi:10.1126/science.abb2507. PubMed PMID: 32075877; PubMed Central PMCID: PMCPMC7164637. eng.
   PubMed Web of Science ®Google Scholar
• Zehender G, Lai A, Bergna A, Meroni L, Riva A, Balotta C, Tarkowski M, Gabrieli A, Bernacchia D, Rusconi S, et al. Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy. J Med Virol. 2020 Mar 29. doi:10.1002/jmv.25794. PubMed PMID: 32222993; PubMed Central PMCID: PMCPMC7228393. eng.
   Web of Science ®Google Scholar
• Eaaswarkhanth M, Madhoun AA, Al-Mulla F. Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality. Int J Infect Dis. 2020;96:459–60. doi:10.1016/j.ijid.2020.05.071.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv. 2020. doi:10.1101/2020.06.12.148726.
   Google Scholar
• Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020 Mar 27;367(6485):1444–48. doi:10.1126/science.abb2762. PubMed PMID: 32132184; PubMed Central PMCID: PMCPMC7164635. eng.
   PubMed Web of Science ®Google Scholar
• Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 Mar 19;17:613–20. doi:10.1038/s41423-020-0400-4. PubMed PMID: 32203189.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines (Basel). 2020 Mar 29;8(2). doi: 10.3390/vaccines8020153. PubMed PMID: 32235387.
   Web of Science ®Google Scholar
• Yuan L, Tang Q, Cheng T, Xia N. Animal models for emerging coronavirus: progress and new insights. Emerg Microbes Infect. 2020 Dec;9(1):949–61. PubMed PMID: 32378471. doi:10.1080/22221751.2020.1764871.
   PubMed Web of Science ®Google Scholar
• Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, Wei Q, Yu P, Xu Y, Qi F, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020 May 7;583:830–33. doi:10.1038/s41586-020-2312-y. PubMed PMID: 32380511; eng.
   PubMed Web of Science ®Google Scholar
• Lu S, Zhao Y, Yu W, Yang Y, Gao J, Wang J, Kuang D, Yang  M, Yang J, Ma C, Xu J. Comparison of SARS-CoV-2 infections among 3 species of non-human primates. Biorxiv. 2020. doi:10.1101/2020.04.08.031807.
   Google Scholar
• Rockx* B TKDdM, van Amerongen G, Haagmans* BL, Herfst S, Bestebroer T, Lamers MM, Oude Munnink BB, van den Brand J, van Run LL P, Sikkema R, Ernst Verschoor3 Langermans4,5, Christian Drosten6 Koopmans1, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 2020. doi: 10.1126/science.abb7314.
   PubMed Web of Science ®Google Scholar
• Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020 Apr 8;368:1016–20. doi:10.1126/science.abb7015. PubMed PMID: 32269068; PubMed Central PMCID: PMCPMC7164390. eng.
   PubMed Web of Science ®Google Scholar
• Kim YI, Kim SG, Kim SM, Kim E-H, Park S-J, Yu K-M, Chang J-H, Kim EJ, Lee S, Casel MAB, et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe. 2020 May 13;27(5):704–709.e2. doi:10.1016/j.chom.2020.03.023. PubMed PMID: 32259477; PubMed Central PMCID: PMCPMC7144857. eng.
   PubMed Web of Science ®Google Scholar
• Munster VJ, Feldmann F, Williamson BN, van Doremalen N, Pérez-Pérez L, Schulz J, Meade-White K, Okumura A, Callison J, Brumbaugh B, et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature. 2020 May 12. doi:10.1038/s41586-020-2324-7. PubMed PMID: 32396922; eng.
   Web of Science ®Google Scholar
• Sia SF, Yan LM, Chin AWH, Fung K, Choy K-T, Wong AYL, Kaewpreedee P, Perera RAPM, Poon LLM, Nicholls JM, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020 May 14;583:834–38. doi:10.1038/s41586-020-2342-5. PubMed PMID: 32408338; eng.
   PubMed Web of Science ®Google Scholar
• Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski LH, Yu J, Maliga Z, Nekorchuk M, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020 May 20:eabc4776. doi:10.1126/science.abc4776. PubMed PMID: 32434946; eng.
   Web of Science ®Google Scholar
• Shanmugaraj B, Malla A, Phoolcharoen W. Emergence of novel coronavirus 2019-nCoV: need for rapid vaccine and biologics development. Pathogens 2020 Feb 22;9(2):148. doi:10.3390/pathogens9020148. PubMed PMID: 32098302.
   PubMed Web of Science ®Google Scholar
• Shang W, Yang Y, Rao Y, Rao X. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines 2020;5:18. PubMed PMID: 32194995; PubMed Central PMCID: PMCPMC7060195. doi:10.1038/s41541-020-0170-0.
   PubMed Web of Science ®Google Scholar
• Lu S. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect 2020;9(1):542–44. doi:10.1080/22221751.2020.1737580. PubMed PMID: 32148172; PubMed Central PMCID: PMCPMC7144304.
   PubMed Web of Science ®Google Scholar
• Caddy S. Developing a vaccine for covid-19. BMJ. 2020 May 4;369:m1790. doi:10.1136/bmj.m1790. PubMed PMID: 32366511.
   PubMed Web of Science ®Google Scholar
• Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020 Apr;580(7805):576–77. PubMed PMID: 32346146; eng. doi:10.1038/d41586-020-01221-y.
   PubMed Web of Science ®Google Scholar
• Draft landscape of COVID 19 candidate vaccines 2020 [ updated 2020 May 11]. [accessed 2020 Jul 14]. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus. Front Microbiol 2019;10:1781. doi:10.3389/fmicb.2019.01781. PubMed PMID: 31428074; PubMed Central PMCID: PMCPMC6688523.
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang J, Liu J, Gao H,  Gao Q, Ning Y, Su N,  Xu G , Jia Y,  Liu Y , Wang H , Li M , Wang N , Chen J, Sun R. Safety and immunogenicity from a Phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12(7):1107–13.
   PubMedGoogle Scholar
• A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated novel coronavirus pneumonia vaccine (Vero cells) Chinese clinical trail registry [ accessed 2020Apr11]. http://www.chictr.org.cn/showprojen.aspx?proj=52227.
   Google Scholar
• Safety and immunogenicity study of inactivated vaccine for prophylaxis of SARS CoV-2 infection (COVID-19). NIH-Clinical Trial.gov; [ accessed 2020 Apr 20]. https://clinicaltrials.gov/ct2/show/NCT04352608?term=Sinovac&cntry=CN&draw=2.
   Google Scholar
• Double-blind, randomized, placebo-controlled phase III Clinical trial to evaluate efficacy and safety in healthcare professionals of the adsorbed COVID-19 (Inactivated) vaccine manufactured by Sinovac 2020 [accessed 2020 Jul 2]. https://clinicaltrials.gov/ct2/show/NCT04456595?term=vaccine&cond=covid-19&draw=2&rank=1.
   Google Scholar
• Evaluation of the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) in healthy population aged 3 years and above: a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial. Chinese Clinical Trail Registry; [ accessed 2020 Apr 29]. http://www.chictr.org.cn/showproj.aspx?proj=53003.
   Google Scholar
• Safety and immunogenicity study of an inactivated SARS-CoV-2 vaccine for preventing against COVID-19: clinicalTrials.gov; 2020 [accessed 2020 June 2]. https://clinicaltrials.gov/ct2/show/NCT04412538?term=vaccine&cond=covid-19&draw=2.
   Google Scholar
• A seamless phase 1, followed by Phase 2 randomized, double-blind, multicenter study to evaluate the safety, reactogenicity, tolerability and immunogenicity of the whole-virion inactivated SARS-CoV-2 Vaccine (BBV152) in healthy volunteers. 2020 [accessed 2020 Jul 7]. http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152.
   Google Scholar
• Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369:77–81. doi:10.1126/science.abc1932.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W,  Zhao Y, Li N, Zhang J, Liang H. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182:1–9. doi:10.1016/j.cell.2020.06.008.
   PubMed Web of Science ®Google Scholar
• Almazán F, DeDiego ML, Sola I, Zuñiga S, Nieto-Torres JL, Marquez-Jurado S, Andrés G, Enjuanes L. Engineering a replication-competent, propagation-defective middle east respiratory syndrome coronavirus as a vaccine candidate. mbio. 2013;4(5):e00650–13. doi:10.1128/mBio.00650-13.
   PubMed Web of Science ®Google Scholar
• Xiang K, Ying G, Yan Z, Shanshan Y, Lei Z, Hongjun L, Maosheng S. Progress on adenovirus-vectored universal influenza vaccines. Human Vaccines % Immunother. 2015;11(5):1209–22. doi:10.1080/21645515.2015.1016674.
   PubMed Web of Science ®Google Scholar
• A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector): Chinese Clinical Trail Registry; [ accessed 2020 Mar 17]. http://www.chictr.org.cn/showprojen.aspx?proj=51154.
   Google Scholar
• A randomized, double-blinded, placebo-controlled phase II clinical trial for recombinant novel coronavirus (2019-nCOV) vaccine (Adenovirus Vector). Chinese Clinical Trail Registry: Chinese Clinical Trail Registry; 2020 [accessed 2020 Apr 10]. http://www.chictr.org.cn/showprojen.aspx?proj=52006.
   Google Scholar
• Zhu F, Li Y, Guan X, Wang  W, Li J, Wu S, Wang B, Wang Z, Wang L, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet (London, England). 2020 May 22. doi:10.1016/s0140-6736(20)31208-3. PubMed PMID: 32450106; eng.
   PubMed Web of Science ®Google Scholar
• An open study of the safety, tolerability and immunogenicity of the drug “Gam-COVID-Vac” vaccine against COVID-19 2020 [ accessed 2020 Jun 18]. https://clinicaltrials.gov/ct2/show/NCT04436471?term=vaccine&cond=covid-19&draw=4.
   Google Scholar
• An open study of the safety, tolerability and immunogenicity of “Gam-COVID-Vac Lyo” vaccine against COVID-19 2020 [ accessed 2020 Jun 18]. https://clinicaltrials.gov/ct2/show/NCT04437875?term=vaccine&cond=covid-19&draw=4.
   Google Scholar
• A study of a candidate COVID-19 vaccine (COV001). NIH-Clinical Trial.gov; [ accessed 2020 Mar 27]. https://clinicaltrials.gov/ct2/show/NCT04324606?term=vaccine&cond=covid-19&draw=2.
   Google Scholar
• van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato V, Bushmaker T, Flaxman A, Ulaszewska M, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv. 2020. doi:10.1101/2020.05.13.093195.
   Google Scholar
• A phase III study to investigate a vaccine against COVID-19 2020 [ updated 2020 12 Jun; 2020 26 May]. https://doi.org/10.1186/ISRCTN89951424
   Google Scholar
• Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines. 2014;13(6):761–74. doi:10.1586/14760584.2014.912134.
   PubMed Web of Science ®Google Scholar
• Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infect Dis Ther. 2020;9:255–74. doi:10.1007/s40121-020-00300-x.
   PubMed Web of Science ®Google Scholar
• Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle vaccine with/without matrix-M adjuvant. 2020.
   Google Scholar
• A phase 1, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety and immunogenicity of SCB 2019, a recombinant SARS-CoV-2 trimeric S protein subunit vaccine for COVID-19 in healthy volunteers: ClinicalTrials.gov; 2020 [updated 2020 Jun 23]. https://clinicaltrials.gov/ct2/show/NCT04405908?term=clover&cond=covid-19&draw=2&rank=1.
   Google Scholar
• A multi-center, double-blind, randomized, placebo parallel controlled, safety and tolerability phase I clinical trial of recombinant novel coronavirus vaccine (CHO Cells) in healthy people between 18 and 59 years of age clinicaltrials.gov2020 [ updated July 2, 2020]. https://clinicaltrials.gov/ct2/show/NCT04445194?term=longcom&draw=2
   Google Scholar
• A randomised, controlled, phase 1 study to evaluate the safety and immunogenicity of a candidate adjuvanted recombinant protein SARS-COV-2 vaccine in healthy adult subjects 2020 [ accessed 2020 July 1]. https://clinicaltrials.gov/ct2/show/NCT04453852?term=vaccine&cond=covid-19&draw=5
   Google Scholar
• A phase 1 randomised, double-blind, placebo-controlled, dosage-escalation, single centre study to evaluate the safety and immunogenicity of an adjuvanted SARS-CoV-2 sclamp protein subunit vaccine (COVID-19 vaccine) in healthy adults aged 18 to 55 years old 2020 [ accessed 2020 12 Jun]. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true
   Google Scholar
• Ren W, Sun H, Gao GF, Chen J, Sun S, Zhao R, Gao G, Hu Y, Zhao G, Chen Y, Jin X, et al. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates. bioRxiv. 2020. doi:10.1101/2020.04.21.052209.
   Google Scholar
• Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.01963.
   Web of Science ®Google Scholar
• Okuda K, Wada Y, Shimada M. Recent developments in preclinical DNA vaccination. Vaccines (Basel) 2014 Jan 13;2(1):89–106. doi:10.3390/vaccines2010089. PubMed PMID: 26344468; PubMed Central PMCID: PMCPMC4494203.
   PubMedGoogle Scholar
• Safety, tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers. NIH-Clinical Trial.gov. [ accessed 2020 Apr 7]. https://clinicaltrials.gov/ct2/show/NCT04336410?term=inovio&cond=covid-19&draw=2&rank=1.
   Google Scholar
• A phase I/IIa, dose-ranging trial to evaluate safety, tolerability and immunogenicity of INO-4800, a prophylactic vaccine against SARS-CoV-2, administered intradermally followed by electroporation in healthy volunteers 2020 [ updated 2020 June 25]. https://clinicaltrials.gov/ct2/show/NCT04447781
   Google Scholar
• A non-randomized, open-label, non-controlled phase I/II study to assess safety and immunogenicity of two doses of intramuscular AG0301-COVID19 (1mg/2mg) in healthy adults clinicaltrials.gov2020 [ accessed 2020 July 9]. https://clinicaltrials.gov/ct2/show/NCT04463472?term=NCT04463472&draw=2&rank=1
   Google Scholar
• A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of novel corona virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects 2020 [ accessed 2020 04 Jul]. http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306&EncHid=&userName=vaccine
   Google Scholar
• A phase 1/2a, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and immunogenicity of GX-19, a COVID-19 preventive DNA vaccine in healthy subjects 2020 [ updated June 26, 2020]. https://clinicaltrials.gov/ct2/show/NCT04445389?term=vaccine&cond=covid-19&draw=3
   Google Scholar
• Martina JE, Loudera MK, Holmana LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune_responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26:6338–43. doi:10.1016/j.vaccine.2008.09.026.
   PubMed Web of Science ®Google Scholar
• Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh M-D, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19:1013–22. doi:10.1016/S1473-3099(19)30266-X.
   PubMed Web of Science ®Google Scholar
• Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 May 20:eabc6284. doi:10.1126/science.abc6284. PubMed PMID: 32434945; eng.
   Google Scholar
• Cohen J. Vaccine designers take first shots at COVID-19. Nature. 2020;368:14–16.
   Google Scholar
• Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19) NIH-clinical trial.gov. [ accessed 2020 February 25]. https://clinicaltrials.gov/ct2/show/NCT04283461?term=vaccine&cond=covid-19&draw=2.
   Google Scholar
• A phase 2a, randomized, observer-blind, placebo controlled, dose-confirmation study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 SARS-COV-2 vaccine in adults aged 18 years and older 2020 [ updated 2020 July 10]. https://clinicaltrials.gov/ct2/show/NCT04405076?term=moderna&cond=covid-19&draw=2.
   Google Scholar
• A multi-site phase I/II, 2-part, dose-escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-2019 using different dosing regimens in healthy adults. EU Clinical Trails Register. [ accessed 2020 Apr 14]. https://www.clinicaltrialsregister.eu/ctr-search/search?query=BNT162-01.
   Google Scholar
• A phase 1/2, placebo-controlled, randomized, observer blind, dose-discovery study to describe the safety, tolerability, immunogenicity, and potential efficacy of SARS-COV-2 RNA vaccine candidates against COVID-19 in healthy adults 2020 [ updated 2020 June 29; accessed 2020 April 30]. https://clinicaltrials.gov/ct2/show/NCT04368728?term=vaccine&cond=covid-19&draw=3.
   Google Scholar
• A first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19 2020 [ accessed 2020 Apr 06]. http://www.isrctn.com/ISRCTN17072692.
   Google Scholar
• A phase 1, partially blind, placebo-controlled, dose-escalation, first-in-human, clinical trial to evaluate the safety, reactogenicity and immunogenicity after 1 and 2 doses of the investigational SARS-CoV-2 mRNA vaccine CVnCoV administered intramuscularly in healthy adults 2020 [ accessed 2020 June 26]. https://clinicaltrials.gov/ct2/show/NCT04449276?term=vaccine&cond=covid-19&draw=6.
   Google Scholar
• A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18–59 years and 60 years and above. 2020.
   Google Scholar
• Wang F, Kream RM, Stefano GB. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci Monit. 2020 May 5;26:e924700. doi:10.12659/MSM.924700. PubMed PMID: 32366816.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A,  Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson AK, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv. 2020. doi:10.1101/2020.06.30.20142570.
   Google Scholar